V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210028228 | 210014002 | 1.6 | 61 | Palliative (P) | 2015-07-29 | 2015-08-03 | CARBOPLATIN + VINORELBINE | 02 | N | 210038996 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210028229 | 210014003 | 1.74 | null | Disease modification (D) | 2013-11-12 | 2013-11-12 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210039007 | UKALL 60+ TRIAL |
| 210028230 | 210031607 | 1.75 | 98 | Palliative (P) | 2014-11-10 | 2014-11-16 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | 02 | N | 210039065 | IVAC |
| 210028231 | 210022732 | 1.68 | 82.1 | Palliative (P) | 2015-11-26 | 2016-04-15 | Nilotinib | N | N | 210039137 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210028232 | 210031608 | 1.75 | 76 | Curative (C) | 2015-09-04 | 2015-09-04 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | N | N | 210039294 | DA |
| 210028233 | 210014007 | 1.6 | 91.2 | Curative (C) | null | 2014-05-15 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | null | 210039506 | GEMCITABINE + OXALIPLATIN |
| 210028234 | 210035180 | 0 | 50 | Disease modification (D) | 2017-08-20 | 2017-08-29 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE | N | N | 210039555 | OFATUMUMAB |
| 210028235 | 210037469 | null | 77.7 | Palliative (P) | 2018-11-02 | 2018-12-21 | Capecitabine + Oxaliplatin 21day | Y | N | 210039555 | ABVD |
| 210028236 | 210038653 | 1.57 | 6.25 | Curative (C) | 2016-03-30 | 2016-04-06 | CISPLATIN + ETOPOSIDE | N | N | 210039663 | CLARITY TRIAL |
| 210028237 | 210014013 | 1.84 | 88.4 | Curative (C) | 2017-05-31 | 2017-06-01 | Cytarabine intrathecal | 02 | null | 210040040 | MPV |
| 210028238 | 210014018 | null | 81.8 | Palliative (P) | 2016-02-03 | 2016-04-21 | Cyclophosphamide High Dose | 2 | N | 210040051 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 210028239 | 210014018 | 0.99 | 88.4 | Palliative (P) | 2017-04-16 | 2017-04-19 | Cytarabine intrathecal | N | null | 210040051 | ABVD |
| 210028240 | 210022736 | null | 94.9 | Curative (C) | 2016-03-12 | 2016-12-15 | MELPHALAN | N | N | 210040164 | CLARITY TRIAL |
| 210028241 | 210014020 | null | 11.4 | Curative (C) | 2018-01-27 | 2018-02-27 | AML16 DA 3+8 | N | null | 210040298 | CYTARABINE HIGH DOSE |
| 210028242 | 210014023 | null | 68.6 | Curative (C) | 2017-05-31 | 2017-06-04 | Cyclophosphamide High Dose | N | null | 210040403 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210028243 | 210014025 | 1.73 | 81.8 | Palliative (P) | 2016-05-31 | 2017-05-02 | ALL Int Guide B Int Maint Ph III | N | N | 210040409 | DOCETAXEL |
| 210028244 | 210014029 | 1.57 | 25 | Adjuvant (A) | 2016-06-26 | 2016-06-26 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | 02 | N | 210040771 | R-EPOCH |
| 210028245 | 210028260 | 1.66 | 38.9 | Curative (C) | 2014-09-01 | 2014-09-24 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210040788 | RCEOP |
| 210028246 | 210014032 | 1.77 | 78.9 | Disease modification (D) | 2018-03-22 | 2018-03-29 | Nilotinib | N | Y | 210040826 | ABVD |
| 210028247 | 210014034 | 1.75 | 81.7 | Disease modification (D) | null | 2018-07-22 | Bexarotene | N | N | 210041159 | UKALL2003 |
| 210028248 | 210014037 | null | 76 | Palliative (P) | 2018-05-06 | 2018-05-12 | Alemtuzumab + Cyclophos TBI Allo | N | Y | 210041235 | CYTARABINE INTRATHECAL |
| 210028249 | 210014039 | null | 82 | Palliative (P) | 2018-02-26 | 2018-03-01 | Cytarabine High Dose | N | null | 210041316 | CYTARABINE INTRATHECAL |
| 210028250 | 210022745 | null | 76.8 | Curative (C) | 2016-10-05 | 2016-10-20 | Lenalidomide 25mg (Cycle 1 to 25) | Y | null | 210041453 | IBRUTINIB + RITUXIMAB |
| 210028251 | 210014041 | 1.73 | null | Palliative (P) | 2015-01-03 | 2015-10-28 | Irinotecan + Temozolomide | 02 | N | 210041453 | CLL210 TRIAL |
| 210028252 | 210014043 | 1.76 | 16.5 | Palliative (P) | 2018-03-29 | 2018-03-29 | CARBOPLATIN + ETOPOSIDE + THIOTEPA | null | N | 210041640 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028253 | 210014045 | 1.84 | 117.5 | Palliative (P) | 2013-05-30 | 2013-06-05 | Cytarabine intrathecal | 02 | N | 210041720 | OFATUMUMAB |
| 210028254 | 210022748 | 1.6 | 49 | Curative (C) | 2019-02-24 | 2019-06-17 | GEM-P | 2 | N | 210041755 | IRINOTECAN + PANITUMUMAB + MDG |
| 210028255 | 210014050 | 1.77 | 16.5 | Palliative (P) | 2018-04-05 | 2018-06-01 | Packer Maintenance Regimen | 02 | null | 210041781 | CLARITY TRIAL |
| 210028256 | 210014055 | 0 | 108.4 | Palliative (P) | 2015-11-09 | 2016-11-15 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 2 | N | 210042046 | UKALL 60+ TRIAL |
| 210028257 | 210014056 | 1.79 | null | Disease modification (D) | 2016-01-11 | 2016-03-27 | ALL UKALL2003 C: Ph VII Maintenance | N | null | 210042047 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210028258 | 210022756 | 1.7 | 81.8 | Palliative (P) | null | 2017-06-27 | Ofatumumab Weekly | null | N | 210042061 | AML19 TRIAL |
| 210028259 | 210014060 | null | null | Curative (C) | 2016-12-22 | 2017-01-26 | IDARUBICIN | N | N | 210003167 | DOCETAXEL + TRASTUZUMAB |
| 210028260 | 210022759 | 0 | 75.6 | Curative (C) | 2015-01-26 | 2015-05-10 | Pemetrexed | N | N | 210012122 | AML18 TRIAL |
| 210028261 | 210028270 | 1.59 | 42.8 | Palliative (P) | 2018-03-15 | 2018-06-15 | IDARUBICIN | 2 | N | 210022690 | CLL210 TRIAL |
| 210028262 | 210014063 | 1.68 | 57.8 | Palliative (P) | 2018-11-10 | 2018-11-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | 210024124 | ICE-R |
| 210028263 | 210014064 | 1.58 | 54.7 | Adjuvant (A) | 2017-12-03 | 2017-12-06 | MITOMYCIN | N | N | 210024514 | CYTARABINE |
| 210028264 | 210014066 | 0 | null | Not known (9) | null | 2017-10-24 | Cytarabine HD + Methotrexate HD | N | N | 210025956 | ALL CONSOLIDATION |
| 210028265 | 210014068 | 1.73 | 12.2 | Palliative (P) | 2018-09-10 | 2018-09-11 | CNS LGG Irinotecan & Bevacizumab | 2 | N | 210025987 | FLUDARABINE + RITUXIMAB |
| 210028266 | 210014068 | 1.72 | 66.6 | Disease modification (D) | 2016-11-11 | 2016-11-12 | Cyclophosphamide High Dose | N | N | 210025987 | ENZALUTAMIDE |
| 210028267 | 210033735 | 0.99 | null | Curative (C) | 2017-06-09 | 2017-09-08 | Bendamustine + Thalidomide +/- Dex | N | null | 210029013 | DAUNORUBICIN + VNCRISTINE |
| 210028268 | 210014069 | 1.75 | null | Palliative (P) | 2019-08-11 | 2019-08-11 | Irinotecan + Modified De Gramont | 2 | N | 210030920 | CLADRIBINE + RITUXIMAB |
| 210028269 | 210014075 | null | 81.899 | Disease modification (D) | 2016-10-21 | 2016-10-29 | Bortezomib +/- Dexamethasone | N | N | 210032826 | DA |
| 210028270 | 210014077 | 1.62 | 70.8 | Disease modification (D) | null | 2018-01-31 | Melphalan oral | null | null | 210032863 | IVAC |
| 210028271 | 210014079 | 1.73 | 0 | Curative (C) | 2018-01-13 | 2018-05-08 | CNS Medbl Std Risk Maint Cisplatin | null | N | 210033781 | IRINOTECAN + MDG |
| 210028272 | 210028274 | 1.53 | 75.4 | Disease modification (D) | 2017-07-16 | 2017-07-16 | Bevacizumab + NIVOLUMAB | 2 | N | 210034307 | DOCETAXEL |
| 210028273 | 210014084 | 1.69 | 75 | Palliative (P) | 2015-11-16 | 2016-06-23 | Olaparib | 02 | N | 210036972 | CARBOPLATIN + PACLITAXEL |
| 210028274 | 210031622 | 1.73 | 70 | Curative (C) | 2017-05-12 | 2017-05-12 | Obinutuzumab | N | N | 210039936 | PILOT TRIAL |
| 210028275 | 210028278 | 1.11 | 92 | Curative (C) | 2018-01-14 | 2018-01-15 | CLL210 TRIAL | N | N | 210040141 | IDARUBICIN |
| 210028276 | 210022776 | 1.72 | 77.5 | Not known (9) | null | 2017-01-26 | Cytarabine intrathecal | N | N | 210041480 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210028277 | 210014088 | 1.78 | 55.6 | Adjuvant (A) | 2019-03-17 | 2019-04-14 | Trastuzumab emtansine (Kadcyla) 1st | 02 | N | 210041640 | R CODOX-M/ R IVAC |